910867-08-2

Basic information

• Product Name: N-[4-(4-Fluorophenyl)-5-[(1E)-3-hydroxy-1-propen-1-yl]-6-isopropyl-2-pyriMidinyl]-N-Methyl-MethanesulfonaMide
• Synonyms: N-[4-(4-Fluorophenyl)-5-[(1E)-3-hydroxy-1-propen-1-yl]-6-(1-Methylethyl)-2-pyriMidinyl]-N-Methyl-MethanesulfonaMide;N-[4-(4-Fluorophenyl)-5-[(1E)-3-hydroxy-1-propen-1-yl]-6-isopropyl-2-pyriMidinyl]-N-Methyl-MethanesulfonaMide
• CAS NO: 910867-08-2
• Molecular Formula: C₁₈H₂₂FN₃O₃S
• Molecular Weight: 379.4489832
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 910867-08-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• CAS DataBase Reference: N-[4-(4-Fluorophenyl)-5-[(1E)-3-hydroxy-1-propen-1-yl]-6-isopropyl-2-pyriMidinyl]-N-Methyl-MethanesulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(4-Fluorophenyl)-5-[(1E)-3-hydroxy-1-propen-1-yl]-6-isopropyl-2-pyriMidinyl]-N-Methyl-MethanesulfonaMide(910867-08-2)
• EPA Substance Registry System: N-[4-(4-Fluorophenyl)-5-[(1E)-3-hydroxy-1-propen-1-yl]-6-isopropyl-2-pyriMidinyl]-N-Methyl-MethanesulfonaMide(910867-08-2)

Safety Data

• Hazardous Substances Data: 910867-08-2(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Upstream product

• 910867-07-1 ethyl (E)-3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonamido)pyrimidin-5-yl]acrylate 
• 912337-58-7 3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(2E)-propenoic acid 
• 1005003-77-9 3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(2E)-propenoyl methyl carbonate 
• 1024024-26-7 methyl 3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(2E)-propenoate 
• 894787-92-9 N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyriinidin-2-yl)-N-methylmethanesulfonamide 
• 642066-70-4 (E)-4,4,5,5-tetramethyl-2-(3-((tetrahydro-2H-pyran-2-yl)oxy) propylene-1-yl)-1,3,2-dioxaborolane 
• 114433-94-2 1-(4-Fluorophenyl)-3-isopropylpropan-1,3-dione 
• 1356998-74-7 2-allyl-1-(4-fluorophenyl)-4-methylpentane-1,3-dione 
• 1356998-75-8 5-allyl-4-(4-fluorophenyl)-6-isopropyl-N-methylpyrimidin-2-amine 
• 1356998-76-9 N-(5-allyl-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide 
• 1356998-78-1 N-(4-(4-fluorophenyl)-6-isopropyl-5-(oxiran-2-ylmethyl)pyrimidin-2-yl)-N-methylmethanesulfonamide 
• 1356998-82-7 (E)-N-(4-(4-fluorophenyl)-5-(3-bromoprop-1-enyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide 
• 890028-66-7 (E)-N-[4-(4-fluorophenyl)-6-isopropyl-5-(3-oxoprop-1-en-1-yl)pyrimidin-2-yl]-N-methyl methanesulfoneamide 

Downstream Products

• 890028-66-7 (E)-N-[4-(4-fluorophenyl)-6-isopropyl-5-(3-oxoprop-1-en-1-yl)pyrimidin-2-yl]-N-methyl methanesulfoneamide 

Relevant articles and documents

Synthesis and Biological Evaluation of Gem-Difluoromethylenated Statin Derivatives as Highly Potent HMG-CoA Reductase Inhibitors

HMG-CoA reductase inhibitors were widely used as lipid-lowing agents through effectively blocking the rate-limiting step of cholesterol biosynthesis. 8 analogs of Rosuvastatin were firstly prepared with different distance and functional group between the

A (E)- 3 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - (N - methyl - N - a sulfuryl amidogen) pyrimidine - 5 - yl] acrolein preparation method

The invention discloses a preparation method of (E)-3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino) pyrimidine-5-yl] acrolein which can be used as a rosuvastatin intermediate. The preparation method comprises the following steps: reacting 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino) pyrimidine-5-yl-formaldehyde with a sulfur ylide reagent under an alkaline condition to generate an epoxide shown in the formula III; then, reducing in the presence of a metal catalyst to generate a compound shown in the formula II; and finally reacting the compound shown in the formula II to generate the target product. The preparation method is simple in process and low in cost; no expensive catalyst is used; the generation of byproducts is reduced effectively so that the post-treatment becomes simple and easy to operate; in addition, the reaction yield is improved greatly; and therefore, the preparation method is quite suitable for large-scale industrial production.

A (E)- 3 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - (N - methyl - N - a sulfuryl amidogen) pyrimidine - 5 - yl] acrolein synthetic method

The invention discloses a method for synthesizing (E)-3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methane sulfonamide) pyrimidine-5-yl] acraldehyde used as a rosuvastatin calcium intermediate. The synthesizing method comprises the following steps: reacting a compound in formula III with substituted sulphonate or substituted sulfinic acid ester in the existence of a metal reagent, generating a compound in a formula II under the effect of an eliminating reagent and converting into a product, wherein in the formula II, R is chosen from -CN. The method is simple in process and low in cost, the expensive catalyst is avoided and the byproduct is effectively reduced, so that the after treatment is simple and easy to operate, the reaction yield is greatly increased and the method is suitable for large scale industrial production. The formulae are as shown in the specification.

Process for the preparation of key intermediates for the synthesis of statins or pharmaceutically acceptable salts thereof

The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.

PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR THE SYNTHESIS OF STATINS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

The invention relates to commercially viable process for the synthesis of key intermediates for the preparation of statins, in particular Rosuvastatin and Pitavastatin or respective pharmaceutically acceptable salts thereof. A new simple and short synthetic route for key intermediates is presented which benefits from the use of cheap and readily available starting materials, by which the conventionally most frequently used DIBAL-H as reducing agent can be avoided.

PROCESS FOR PREPARING ROSUVASTATIN CALCIUM

The present invention relates to an improved process for preparing Rosuvastatin calcium of Formula I.

PROCESS FOR PREPARING ROSUVASTATIN CALCIUM

The present invention relates to an improved process for preparing (2E)-3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-propenal of Formula I which is an intermediate useful in the preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methyl-sulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoicacid] calcium salt of Formula II

AN IMPROVED PROCESS FOR PREPARING ROSUVASTATIN CACLIUM

The present invention relates to an improved process for preparing (2E)-3-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-propenal of Formula I which is an intermediate useful in the preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoicacid] calcium salt of Formula II

PROCESS FOR THE PREPARATION OF ROSUVASTATIN

A process for the manufacture of a compound of formula (V), useful for making rosuvastatin, by a stereoselective aldol reaction is described.

PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES

A process for the manufacture of a compound of formula (V), useful for making rosuvastatin, by a stereoselective aldol reaction is described. Novel intermediates and processes to make them are also described.